Search results
Results from the WOW.Com Content Network
Typical antipsychotics (also known as major tranquilizers, and first generation antipsychotics) are a class of antipsychotic drugs first developed in the 1950s and used to treat psychosis (in particular, schizophrenia). Typical antipsychotics may also be used for the treatment of acute mania, agitation, and other conditions.
The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), [1] [2] are a group of antipsychotic drugs (antipsychotic drugs in general are also known as tranquilizers and neuroleptics, although the latter is usually reserved for the typical antipsychotics) largely introduced after the 1970s and used to treat psychiatric ...
1.1 Antipsychotic esters. 1.1.1 Typical antipsychotics. 1.1.2 Atypical antipsychotics. 2 See also. 3 References. 4 External links. Toggle the table of contents.
The difference between first- and second-generation antipsychotics is a subject of debate. The second-generation antipsychotics are generally distinguishable by the presence of 5HT2A receptor antagonism and a corresponding lower propensity for extrapyramidal side effects compared to first-generation antipsychotics. [15]
Thioridazine (Mellaril or Melleril) is a first generation antipsychotic drug belonging to the phenothiazine drug group and was previously widely used in the treatment of schizophrenia and psychosis. The branded product was withdrawn worldwide in 2005 because it caused severe cardiac arrhythmias.
Benperidol [1] binds D 2 and some serotonin receptors. [16] It is absorbed very easily and has a high first pass effect. [16] Chlorpromazine binds D 3 with the highest affinity, but also binds D 1, D 2, D 4 and D 5 [2] [3] Chemical Structure of typical antipsychotic chlorpromazine. Clopenthixol [1] Droperidol is used as an antipsychotic and ...
[1] Second-generation (atypical) antipsychotics: The concept of "atypicality" is from the finding that second generation antipsychotics (SGAs) have a greater serotonin/dopamine ratio than earlier drugs, and might be associated with improved efficacy (particularly for the negative symptoms of psychosis) and reduced extrapyramidal side effects.
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2]